Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 368 | 432 | 224 | 441 | 276 |
Receivables | 41 | 31 | 28 | 26 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 6 | 5 | 5 | 5 |
Other Current Assets | 42 | 30 | 10 | 7 | 6 |
Total Current Assets | 459 | 499 | 266 | 479 | 307 |
Net Property & Equipment | 0 | 1 | 1 | 2 | 1 |
Investments & Advances | 57 | 5 | 112 | 36 | 39 |
Other Non-Current Assets | 8 | 11 | 13 | 16 | 12 |
Deferred Charges | 91 | 61 | 27 | 32 | 46 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 5 | 3 | 5 | 3 |
Total Assets | 622 | 583 | 424 | 572 | 412 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 12 | 7 | 11 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 87 | 45 | 40 | 35 | 30 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 14 | 0 | 0 | 2 |
Total Current Liabilities | 105 | 72 | 48 | 47 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 10 | 9 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 115 | 82 | 48 | 48 | 41 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 739 | 662 | 591 | 516 | 457 |
Retained Earnings | 403 | 296 | 195 | 82 | -24 |
Other Equity | 1 | -1 | 0 | 0 | 0 |
Treasury Stock | 635 | 456 | 410 | 76 | 63 |
Total Shareholder's Equity | 507 | 502 | 376 | 523 | 371 |
Total Liabilities & Shareholder's Equity | 622 | 583 | 424 | 572 | 412 |
Total Common Equity | 507 | 502 | 376 | 523 | 371 |
Shares Outstanding | 103.00 | 107.60 | 115.40 | 116.10 | 114.20 |
Book Value Per Share | 4.92 | 4.66 | 3.26 | 4.51 | 3.25 |
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 473 | 411 | 368 | 355 | 363 |
Receivables | 54 | 62 | 41 | 35 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 7 | 8 | 8 | 7 |
Other Current Assets | 26 | 24 | 42 | 34 | 30 |
Total Current Assets | 561 | 503 | 459 | 432 | 433 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 19 | 40 | 57 | 60 | 0 |
Other Non-Current Assets | 8 | 8 | 8 | 9 | 9 |
Deferred Charges | 112 | 98 | 91 | 87 | 78 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 6 | 7 | 7 | 4 |
Total Assets | 715 | 656 | 622 | 594 | 525 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 19 | 13 | 17 | 17 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 81 | 85 | 87 | 91 | 71 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 14 | 14 |
Total Current Liabilities | 101 | 97 | 105 | 122 | 93 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 12 | 11 | 10 | 10 | 10 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 118 | 108 | 115 | 132 | 103 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 781 | 758 | 739 | 722 | 696 |
Retained Earnings | 466 | 430 | 403 | 371 | 340 |
Other Equity | 0 | 0 | 1 | 0 | 0 |
Treasury Stock | 651 | 641 | 635 | 632 | 614 |
Total Shareholder's Equity | 596 | 548 | 507 | 462 | 422 |
Total Liabilities & Shareholder's Equity | 715 | 656 | 622 | 594 | 525 |
Total Common Equity | 596 | 548 | 507 | 462 | 422 |
Shares Outstanding | 104.40 | 104.10 | 103.00 | 103.00 | 102.50 |
Book Value Per Share | 5.71 | 5.26 | 4.92 | 4.48 | 4.11 |